Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with ...

These five companies combine reasonable valuations with aggressive expansion plans across autos, energy, recycling and solar ...

Bristol-Myers Squibb Company targets upper-end 2026 guidance on Breyanzi, Camzyos & Reblozyl growth; ASCO 2026 catalysts ...

GTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to ...

Issued on behalf of GT Biopharma, Inc. Key Takeaways - First patient dosed in Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager — the third TriKE® program to enter clinical ...

Chinese lithium producer Ganfeng Lithium announced that its 400 Wh/kg solid-state battery has completed ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III ...

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse eventsActivity of the combined regimen ...

Paligenosis defines a tightly controlled program through which terminally differentiated cells re‑enter the cell cycle and ...

Significant progress in NASA's regenerative fuel cell technology enhances energy storage for Moon missions, ensuring power ...

SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company developing rationally designed molecular glue ...

Proteomics uncovered nearly 200 proteins that fluctuate across the menstrual cycle, offering new clues into reproductive biology and diagnosing disorders.